The Centers for Medicare & Medicaid Services (CMS) announced significant price reductions for 15 high-cost Medicare Part D drugs, including treatments for cancer (Ibrance, Xtandi, Pomalyst), diabetes (Ozempic, Janumet), and lung/heart conditions (Ofev, Trelegy), with new negotiated prices taking effect January 1, 2027, aiming for massive savings (38% to 85%) for seniors via the Inflation Reduction Act's negotiation program. These cuts, part of the second negotiation cycle, reflect a substantial $12 billion savings in Medicare spending and aim to reduce out-of-pocket costs for millions of beneficiaries.
Maximum Fair Prices (MFPs) for these 15 drugs will take effect January 1, 2027…
